S
Sally P. Stenning
Researcher at Medical Research Council
Publications - 99
Citations - 11978
Sally P. Stenning is an academic researcher from Medical Research Council. The author has contributed to research in topics: Cancer & Testicular cancer. The author has an hindex of 38, co-authored 98 publications receiving 10817 citations. Previous affiliations of Sally P. Stenning include University of Manchester & Emory University.
Papers
More filters
Journal ArticleDOI
Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)
Peter Johnson,John Radford,Michael Cullen,Matthew R. Sydes,Jan Walewski,Andrew Jack,Kenneth A. MacLennan,Sally P. Stenning,S Clawson,Paul Smith,W David J Ryder,Barry W. Hancock +11 more
TL;DR: There was no evidence of significant difference in EFS or OS between ABVD and MDRs in the trial overall or if the two MDR versus ABVD comparisons are considered separately, and ABVD remains the standard for treatment of advanced HL.
Journal ArticleDOI
18Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group
Robert Huddart,Michael O'Doherty,Anwar R. Padhani,Gordon J. S. Rustin,GM Mead,Johnathan K Joffe,Paul Vasey,S. J. Harland,John P Logue,Gedske Daugaard,S F Hain,SJ Kirk,Jane E. Mackewn,Sally P. Stenning +13 more
TL;DR: Though PET identified some patients with disease not detected by computed tomography scan, the relapse rate among PET negative patients remains high and the results show that 18FDG PET scanning is not sufficiently sensitive to identify patients at low risk of relapse in this setting.
Journal ArticleDOI
Randomized Trials in 2466 Patients With Stage I Seminoma: Patterns of Relapse and Follow-up
Graham M. Mead,Sophie D. Fosså,R. Timothy D. Oliver,Johnathan Joffe,Robert Huddart,J. Trevor Roberts,Philip Pollock,Rhian Gabe,Sally P. Stenning +8 more
TL;DR: This large and mature dataset from three randomized trials has provided support for the use of either radiation therapy or carboplatin therapy as adjuvant treatment for stage I seminoma.
Journal ArticleDOI
Postchemotherapy residual masses in germ cell tumor patients: Content, clinical features, and prognosis
Sally P. Stenning,M. Constance Parkinson,Cyril Fisher,Graham M. Mead,A B A Patricia Cook,Sophie D. Fossa,Alan Horwich,William G. Jones,Edward S. Newlands,R. Timothy D. Oliver,A. Elizabeth Stenwig,Peter M. Wilkinson +11 more
TL;DR: In a retrospective study that included a detailed histopathologic review, the clinicopathologic features of patients with germ cell tumors and resectable residual masses after chemotherapy were assessed.
Journal ArticleDOI
High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis
TL;DR: A benefit is suggested from high-dose chemotherapy as first-salvage treatment in patients with relapsed or refractory non-seminomatous germ-cell tumors, but this benefit is lower than expected from previous phase I/II studies.